Gastrointestinal Cancer News

This guest commentary from Karen Simon, MD, of the Ventura County Gastroenterology Medical Group , responds to the recent cover story in Healio Gastroenterology and Liver Disease on noninvasive colorectal cancer screening options, and provides additional perspective on the benefits of Cologuard (FIT-fecal DNA test; Exact Sciences).

Cancer prevention is the most compelling reason for parents to have their teenagers vaccinated against HPV regardless of their confidence in the vaccine, according to findings published in Cancer Epidemiology, Biomarkers & Prevention.

Individuals who received a false-positive breast or prostate cancer screening appeared more likely to undergo screening in the future, according to findings published in Cancer.

Survivin, an inhibitor of apoptosis protein, may be an attractive target for a variety of immunotherapeutic approaches for cancer, according to study results.

Rivaroxaban significantly reduced venous thromboembolism recurrence among patients who had cancer and VTE compared with dalteparin, according to findings published in Journal of Clinical Oncology.

Researchers at University of Pennsylvania are investigating anti-CD40 antibodies in a number of combinations in pancreatic cancer and other malignancies in which the baseline line immune response against the tumor is insufficient.

Electronic chromoendoscopy improved adenoma and neoplasia detection rates during colonoscopies in a study published in Clinical Gastroenterology and Hepatology.

WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, Karen L. Woods, MD, president of the American Society for Gastrointestinal Endoscopy, announces a public service campaign the society launched in conjunction with CDx Diagnostics to inform the public about the link between chronic heartburn and esophageal adenocarcinoma.

Nurse practitioners already engaged in colorectal cancer screening can further improve the rates of screening, according to a survey conducted in a partnership with the American Association of Nurse Practitioners.

Fruquintinib significantly extended OS compared with placebo among adults with metastatic colorectal cancer who underwent at least two prior lines of chemotherapy, according to results of a randomized phase 3 study conducted in China.